
Abbott to table $25bn bid for medical device maker St Jude?
pharmafile | August 27, 2015 | News story | Manufacturing and Production, Sales and Marketing |Â Â Abbott Laboratories, mergers and acquisitions, st jude medicalÂ
Abbott Laboratories is said to be preparing a $25 billion takeover bid for medical device maker St Jude Medical.
Illinois-based Abbott has been advised by JPMorgan and Citi for several weeks, and preparing financing for a cash and shares offer, say sources familiar with the matter, though at this point, a bid has not yet been made. An Abbott spokesman has denied that the company intends to, while St Jude has yet to comment on the possibility.
Minnesota-based St Jude and Abbott-headquartered in Illinois- already collaborate on cardiovascular devices, and sell their portfolio of products jointly to hospitals and other healthcare providers. It is thought a full merger would be a logical step that would afford the larger company greater leverage in negotiations with buyers.
The anticipated bid comes in a period of frantic merger and acquisitions activity in the pharma sector that has totalled more than $400 billion already in 2015 to-date. St Jude Medical itself recently agreed to acquire fellow medical-device manufacturer Thoratec for about $3.4bn. St Jude has a market capitalisation of about $19bn.
It is assumed Abbott considered a move for St Jude earlier this year, but waited for the outcome of Teva’s pursuit of Mylan, in which Abbott holds a 15% stake. Teva ultimately gave up on the acquisition in July, yet Abbott is clearly still confident it can fund the St Jude deal.
Joel Levy
Related Content

Transactions in the pharma sector: Through the EU merger review looking-glass
With mergers and acquisitions back in full swing after a period of drought, Alec Burnside …

FDA warning slams St Jude’s “inadequate response” to device failures
St Jude Medical has been hit with a warning letter from the FDA over the …

Abbott’s Zika virus test given FDA authorisation
The threat of the Zika virus, though it may have disappeared from the headlines, is …






